Quick Answer
Celldex Therapeutics, Inc. reported Revenue (ASC 606) of $1.54 million for fiscal year 2025.
Celldex Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $1.54M | -78.0% |
| 2024 | $7.02M | +2.0% |
| 2023 | $6.88M | +192.0% |
| 2022 | $2.36M | -49.3% |
| 2021 | $4.65M | -37.3% |
| 2020 | $7.42M | +107.6% |
| 2019 | $3.57M | -62.5% |
| 2018 | $9.54M | -25.2% |
| 2017 | $12.74M | +87.8% |
| 2016 | $6.79M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $730.0K | -70.8% | +5.0% |
| March 31, 2025 | $695.0K | +345.5% | -78.2% |
| September 30, 2024 | $3.19M | +110.3% | +27.7% |
| June 30, 2024 | $2.50M | +832.1% | +1501.3% |
| March 31, 2024 | $156.0K | -83.9% | -89.7% |
| September 30, 2023 | $1.52M | +272.7% | +466.0% |
| June 30, 2023 | $268.0K | +64.4% | -72.3% |
| March 31, 2023 | $967.0K | +455.7% | +137.6% |
- Celldex Therapeutics, Inc. showed a decrease of -78.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Celldex Therapeutics, Inc.’s revenue (asc 606) has declined by 77.2% (from $6.79 million to $1.54 million).
- The most recent figure is from Celldex Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: